American Society of Hematology

Figure 2.

$Figure 2. PFS in selected study subgroups. (A) Forest plot and hazard ratios for PFS per IRC assessment on duvelisib or ofatumumab monotherapy for predefined subgroups within the total study population. Kaplan-Meier curves of PFS per IRC assessment (B) and investigator assessment (C) in the subgroup of patients with del(17p)/TP53 mutation. In this high-risk subgroup, median PFS was 12.7 months and 9.0 months (HR = 0.40, P = .0002) by IRC assessment and 13.8 months and 9.5 months (HR = 0.41, P = .0003) by investigator assessment for duvelisib and ofatumumab, respectively. “Refractory/early relapse” indicates refractory/early relapse to purine analog-based therapy; “prior anticancer therapy” indicates most recent prior anticancer therapy from randomization. LCL, lower confidence limit; UCL, upper confidence limit.$

PFS in selected study subgroups. (A) Forest plot and hazard ratios for PFS per IRC assessment on duvelisib or ofatumumab monotherapy for predefined subgroups within the total study population. Kaplan-Meier curves of PFS per IRC assessment (B) and investigator assessment (C) in the subgroup of patients with del(17p)/TP53 mutation. In this high-risk subgroup, median PFS was 12.7 months and 9.0 months (HR = 0.40, P = .0002) by IRC assessment and 13.8 months and 9.5 months (HR = 0.41, P = .0003) by investigator assessment for duvelisib and ofatumumab, respectively. “Refractory/early relapse” indicates refractory/early relapse to purine analog-based therapy; “prior anticancer therapy” indicates most recent prior anticancer therapy from randomization. LCL, lower confidence limit; UCL, upper confidence limit.

This Feature Is Available To Subscribers Only